Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Observational

Motivation, Learning and Decision Making in Changing Environments

NCT07314112 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-01
Last updated
2026-01-07

Condition(s) studied

Neurocognitive ModelDecision-Making

Study summary

The main objective of this study is to develop a models of sequential decision-making, learning and motivation that includes emotions as driving forces of adaptive behaviour. Using functional magnetic resonance imaging (fMRI), the investigators will test the hypotheses that distinct parts of the prefrontal cortex play specific roles in naturalistic decision-making.

The main hypothesis is that distinct regions of the prefrontal cortex will be differentially involved in learning, motivation, and decision-making in naturalistic tasks. More specifically, the investigators hypothesise that by using a novel set of tasks they have designed in combination with fMRI, they can construct a neurocognitive model that explains how humans make adaptive decisions in dynamic and temporally extended reward environments.

A key region that the investigators believe will play a role in representing the internal and external parameters necessary for adaptive behaviours in the tasks is the anterior cingulate cortex. Depending on the task requirements, this region will further interact with other distinct prefrontal regions such as the frontal pole or dorsolateral prefrontal cortex.

Secondary hypotheses will also be investigated, specific to each specific task.

All data will be collected during a single visit lasting approximately 3.5 hours for each participant. Participants will perform a cognitive task inside the MRI scanner. Each participant will perform only one of the three possible cognitive conditions/tasks (Treasure Hunt, Fastest Queue, or Farm Game).

Each task is presented in the form of a video game played on a computer. Participants play a character who makes repeated choices. Participants are asked to try to collect as many points as possible within a limited time frame (Farm Game) or with limited trials (Fastest Queue and Treasure Hunt).

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age between 18 and 45 * Fluent in French (reading and speaking) * Membership or entitlement to a social security plan * Have given written, informed consent to take part in the study * Normal or corrected-to-normal vision * Right-handed * Body mass index (BMI) between 18.5 and 30 Non-inclusion Criteria: * contraindication to MRI: pacemaker, heart battery, cardiac defibrillator, certain heart valves or neurosurgical clips, cochlear implant, implanted automated injection systems (insulin pump), intraocular metal projectiles, people who work or have worked with metals (excluding X-rays prior to MRI). * under guardianship or curatorship or deprived of their liberty * Participating in a clinical trial or in a period of exclusion from a previous clinical trial * Breast-feeding or pregnant women * claustrophobia * Neurological disorder or severe chronic illness (diabetes, heart, kidney, lung or liver disease, inflammatory disease, psychiatric illness, etc.). * The participant does not wish to be informed of any abnormalities detected during the MRI examination.

Primary outcome measure(s)

  • Functional brain activity — baseline
    Brain activity will be indirectly measured using the BOLD (blood-oxygen-level dependent) signal to test the neural correlates of our key task variables extracted using our cognitive models to infer potential neural mechanisms in our neurocognitive model.

Trial sites (1)

FacilityCityRegionStatus
INSERM Bron France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07314112 on ClinicalTrials.gov ↗ ← All trials in France